Receptor.AI opens peptide discovery platform to outside researchers

Receptor.AI has opened access to its end-to-end peptide discovery platform, giving external research teams a new way to design and optimize therapeutic peptides using structure-guided tools. The launch includes a first SaaS release for affinity optimization, plus benchmark data and a white paper that back the platform’s modeling claims.

Why it matters: - Receptor.AI is turning an internal peptide design system into a commercial platform for outside research teams. - The offering aims to help scientists move from a binding hit to prioritized peptide candidates faster and with more structural context. - The platform also expands access to peptide chemistries that are often difficult to model in standard workflows.

What happened: - Receptor.AI opened access on October 14, 2026, to its End-to-End Peptide Discovery Platform. - External research teams can now use the platform to design and optimize therapeutic peptides. - The first SaaS release, available October 14, provides structure-guided affinity optimization. - Other platform capabilities remain available through collaborative discovery programs and are planned for future SaaS releases. - Receptor.AI also released a white paper describing the platform methodology and validation results, along with four benchmark datasets.

The details: - The platform supports hit identification, peptide–target complex modeling, affinity optimization, passive membrane permeability prediction and multiparameter design. - ForceFold models peptide binding by combining physics-based search across receptor states, peptide conformations and docking poses with an all-atom co-folding model guided by proprietary conditioning adaptors. - When more than one binding mode appears plausible, ForceFold keeps those alternatives for additional evaluation. - The platform parameterizes non-canonical residues in advance, including D-isomers, N-methylated residues and beta- and gamma-amino acids. - Cross-linker attachment groups and backbone modifications are also parameterized in advance. - Researchers can use those chemistries in conformational sampling, docking, scoring and molecular dynamics without configuring them separately for each project. - Affinity and permeability are evaluated in the same workflow. - The platform ranks candidates by relative affinity in the modeled complex and assesses passive membrane permeability for the same candidates. - Permeability prediction combines a conformation-sensitive AI model with two physics-based tiers for candidates the AI model cannot assess confidently. - QuorumMap starts from an existing peptide and a defined set of allowed substitutions, then searches the resulting chemical space and prioritizes variants for more computation and synthesis. - StratAI coordinates the broader design-make-test-analyze cycle and uses laboratory results to guide later optimization rounds.

Between the lines: - Therapeutic peptide design is hard because small sequence changes can alter a peptide’s shape and binding behavior in unpredictable ways. - Receptor.AI is positioning structure-guided modeling as a way to narrow the number of peptides that need to be synthesized. - The launch also signals a broader shift from single-point modeling toward a connected design workflow that includes affinity, permeability and iterative experimental feedback. - The benchmark data are meaningful, but they are still component-level results rather than proof of end-to-end drug development speed gains.

What's next: - Receptor.AI plans additional SaaS releases for capabilities that are now only available through collaborative discovery programs. - Access is available through SaaS subscriptions, commercial licenses and collaborative discovery agreements. - The company will likely use the new platform launch and benchmark package to support partner adoption and future program work.

The bottom line: - Receptor.AI is offering outside teams a structure-guided peptide design platform that connects binding-mode modeling, chemistry expansion and candidate prioritization in one workflow.